Rajib Dutta1* and Swatilekha Roy Sarkar2#
1MD, Neurology, India
2MDS, Consultant Orthodontist, India
*Corresponding Author: Rajib Dutta, MD, Neurology, India. E-mail: firstname.lastname@example.org
Received: December 17, 2019; Published: December 23, 2019
Pain is considered as one of the most important non-motor symptom of Parkinson’s disease (PD) which is frequently overlooked in medical practice. Many patients find it more distressing as compared to the motor symptoms. It is a debilitating symptom with a high prevalence in PD population. It is often underestimated and not treated adequately by clinicians. Quality of life and activities of daily living is severely impaired. The path mechanism of pain in PD is complex and several neurotransmission system is involved which includes glutamergic, serotonergic, noradrenergic, GABAergic, dopaminergic. The fine balance between glutamate and dopamine levels are not maintained in blood and brain in PD patients which somehow explains the neurobiology. Several pharmaceutical agents are present for treatment of pain however the greatest reductions were found with safinamide. Safinamide is now considered as an important adjunct to standard parkinsonian medication for alleviating pain in PD.
Keywords: Safinamide; Pain; Parkinsons Disease; Glutamate; Dopamine
Citation: Rajib Dutta and Swatilekha Roy Sarkar. “Role of Safinamide in controlling Pain in Parkinsons Disease". Acta Scientific Microbiology 3.1 (2020): 31-36.
Copyright: © 2020 Rajib Dutta and Swatilekha Roy Sarkar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.